Whatever the formulation in your weight management product, there is now a seal to make it even better

BPL1 is ADM's probiotic strain with significant results in visceral fat and abdominal circumference reduction. Its efficacy has been verified, both with living strains and when heat-killed, thereby providing for application in solid and in liquid formulas. This all being said, BPL1 is already a benchmark probiotic for important nutrition brands. However, if you will allow, we can also be the seal of nutritional quality that your clients are looking for.

BPL1. Let us Be Part of your products. Be Part of your brands. Be Part of your business.

www.BPL1.com

POWERED BY BIOPOLIS

POWERED BY BIOPOLIS

POWERED BY BIOPOLIS

A new generation of probiotic strains, by ADM Biopolis

BPL1 in focus

A GAME CHANGER

POWERED BY BIOPOLIS

THE NEXT MOST WELL-RECOGNIZED AND SYNERGISTIC PROBIOTIC DEVOTED TO WEIGHT MANAGEMENT AND METABOLIC HEALTH

Over the last decade, an increasing amount of medical research has focused on the role of weight management and metabolism.

A naturally occurring bacteria, extracted directly from healthy, breast-fed children

Positively tested in biofunctionalities against competitors

Well documented strain - Fully gene characterization - Patent protected - Six papers published in peer reviewed journals

Obesity management by means of - Fat reduction - Waist circumference reduction - Satiety increase - Strong antioxidant and anti-inflammatory effect

Works both alive and heat-killed

Favorably tested synergies with other probiotic strains and prebiotics

BPL1 at a glance

Why BPL1

POWERED BY BIOPOLIS

Certain conditions, such as cholesterol, obesity and other metabolic disorders, have a proven interest and metabolic health component.

ADM Biopolis’ Bifidobacterium lactis BPL1 is devoted to body fat reduction and cholesterol content and antioxidant and anti-inflammatory activity.

Targeting one of the top hot topics in our days: fulfilling people’s needs

1Well-recognized probiotic strain with robust and solid scientific background

2Perfect for combinations withOther probiotic strains and other ingredients

3

OUR COMMITMENT WITH A HEALTHIER WORLDADM Biopolis is more than a regular manufacturer of probiotics. We have been able to understand current world’s needs and serve our science to fulfill them. As per our expertise, we can focus our science backed knowledge on health-related indications that are of society’s interest.

According to the World Health Organization (WHO),

“overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. A crude population measure of obesity is the body mass index (BMI), a person’s weight (in kilograms) divided by the square of his or her height (in metres). A person with a BMI of 30 or more is generally considered obese. A person with a BMI equal to or more than 25 is considered overweight. Overweight and obesity are major risk factors for a number of chronic diseases, including diabetes, cardiovascular diseases and cancer. Once considered a problem only in high income countries, overweight and obesity are now dramatically on the rise in low- and middle-income countries, particularly in urban settings.”

It is then undeniable that high cholesterol, obesity and other metabolic disordes, have a proven public interest and metabolic health component. Referring again to the World Health Organization (WHO), “an escalating global epidemic of overweight and obesity - the so called globesity – is taking over many parts of the world”.

ADM Biopolis’ Bifidobacterium lactis BPL1 is devoted to body fat reduction and cholesterol content and antioxidant and anti-inflammatory activity, perfectly complementing a healthy diet and physical activity habits.

10 facts you should know about obesityaccording to WHO

Overweight and obesity are defined as “abnormnal or excessive fat accumulation that may impair health”

1. More than 1.9 billion adults were overweight in 2016, and 650 million obese

2.

Globally, 41 million preschool children were overweight in 2016

3. Overweight and obesity are linked to more deaths worldwide than underweight

4. For an individual, obesity is usually the result of imbalance between calories consumed and calories expended

5.

Supportive environment and communities are fundamental in shaping people’s choices and preventing obesity

6. Children’s diet and physical activity habits are influenced by their surrounding environment

7. Eating a healthy diet can help prevent obesity

8.

Regular physical activity helps maintain a healthy body

9. Curbing the global obesity epidemic requires a population-based multisectoral, multi-disciplinary, and culturally relevant approach

10.

Physical activity

Healthy diet POWERED BY BIOPOLIS

Our unique BPL1 development strategyTo create a microbiome modulating tool able to help us face our current global health challenges, we screened our large collection of human-isolated strains with the intention to identify a bacteria with a strong fat reduction capacity.

BPL1 was identified as a result of this endeavor. Its safety, regulatory status and scale-up to industrial volumes were developed in the following years, together with a strong scientific dossier supporting its effect in humans.

4. Finally, a human clinical trial confirmed the effect of the strain, both alive and heat-killed, in reducing key obesity-related factors. More precisely, statistically significant results were found in the reduction of abdominal fat and waist circumference on a 12-week clinical trial with 135 overweight subjects, that was randomized, parallel, double-blind and placebo-controlled.

3. The results found in C. elegans were then transferred to two murine models for metabolic disorders: cafeteria-fed-obese rats and genetically obese (Zücker) rats. The trials were run against placebo conditions and, according to the previously obtained results, the metabolic modulation capacity of the strain was confirmed in both studies.

1. As with the rest of ADM Biopolis’ probiotic collection, BPL1 was isolated from healthy humans, in particular from the faeces of a breast-fed baby under three months old, according to FAO/WHO guidelines. All the pertinent safety evaluations were performed, including genome sequencing, and antibiotic resistance assays among others . Bifidobacterium lactis subsp. lactis BPL1 is in the QPS list and has self-affirmed GRAS status in the US

POWERED BY BIOPOLIS

2. Our screening technology behind the identification of BPL1 was founded in the use of Caenorhabditis elegans as an In vivo model for fat reduction. This well-established model organism allows for the identification of probiotic effects in an environment that can then be confidently extrapolated to humans. BPL1 showed the highest body-fat reduction among >35 strains and mechanisms were further deciphered with transcriptomic and metabolomic experiments. This approach confirmed that the main metabolic pathways modulated by BPL1 in the worm were also present in humans and the strain had a strong antioxidant effect. Furthermore, the ability of BPL1 to reduce fat content even when it was in a heat-killed state, was also identified in this set of experiments.

A TECHNOLOGICAL BREAKTHROUGHA unique probiotic strain that works both alive and inactivated or heat-killed

F&B applications

DS/Pharma applications

Infant Nutrition applications

Probiotics are live microor-ganisms that when admi-nistered in adequate amounts, confer a health benefit on the host. However, the beneficial health effect of a microor-ganism can be due to its celular components, not needing the organism to be alive for it to perform its function. We have

BPL1 is perfect for combination with other ingredients

BPL1 can be combined with other ingredients and/or other probiotic strains for synergistic purposes tackling different health related claims.

ADM Biopolis has an extensive portfolio of probiotic strains that allows the development of different concepts by a

This types of synergies are exemplified by the combination of heat-killed BPL1 with the dietary and highly functional soluble fiber Fibersol. A synergistic effect in fat reduction was observed when the two ingredients where combined in three different types of beverages.

More ADM potential ingredients combination with BPL1

Proteins Ingredients Systems

Ingredients Systems

Sweeteners Proteins

• Ancient Grains• Custom Proteins• Edible Beans and Pulses• Nuts and Seeds• Protein Crisps and Puffs• Protein Flours and Grits• Protein Isolates and Concentrates• Soy Proteins• Textured Proteins

• Colors• Extracts• Fiber• Flavors• Seasonings• Specialty Proteins• Sweeteners• Vitamins/Minerals

• Corn Syrup• Dry Honey and Dry Molasses• Monk Fruit• Stevia• Sucralose• Sugar Products and Blends• Sweetness From Fruit• Sweetness Taste Modifi ers

• Acid Stable Blue• Annatto• Beetroot• Beta-Carotene• Paprika• Spirulina Vegetable and Fruit Anthocyanins• Turmeric

• Extracts and Distillates for Clean- and Clear-Label• From-the-Name Source Flavors• Mint Oils and Flavors• Natural Flavor Systems• Real Foodstuffs• Taste Modifi ers• Varietal and Origin-Specifi c Flavors

Baby Food, Infant Formula and Infant Cereal

Chewing Gums Nutritional Gummies

Fresh Fortifield Milk w/ Probiotics

Cookies and Rice Cakes

Liquid Beverages

Ice CreamsPowder Beverages

Plant Based Yoghurt

Bites

Yoghurt (Powder)

Tablets Capsules Sticks Liquid Forms(Drops,

Sachets

Gelatin Capsules Suppositoriesand Pessaries

Chewing Gums GummiesCreams

demonstrated by means of our animal trials as well as in our human clinical study, that BPL1 also works when killed by heat-treat-ment (121 °C, 30 min). In other words, the efficacy and viability of the strain remains the same regard-less its form (i.e. alive or inactivated/heat-killed).

This represents a disrup-tion within the probiotics space. With BPL1, we can offer a unique Bifidobacte-rium strain with a strong scientific dossier that can be added to any F&B and Dietary Supplement application, especially those ones where traditio-nal probiotics could not be added before due to technological reasons.

rational combination of them. Prove of this are the two BPL1-containing probiotic consortia for skin health, psoriasis and atopic dermatitis.

Furthermore, ADM, with its extensive portfolio and experience in product development can provide holistic solutions for every

potential client. Within this extensive portfolio and among many other ingre-dients, ADM has prebiotics, plant-based proteins, natural flavors, extracts and distillates, natural taste and flavor modifiers, acidulants, emulsifiers, vitamins, DHA or plant sterols.

THE SCIENCE BEHIND BPL1

POWERED BY BIOPOLIS

Human Clinical Trial

Our latest assessment of the effects of BPL1 has been a clinical trial performed with abdominally obese subjects. Results of this research have been published in the top journal on obesity and metabolic disorders, the International Journal of Obesity from Nature Publishing Group (IF = 5.16). The clinical trial involved 135 subjects (>18 years old, mean age: 42), 126 of which finished the complete treatment after three months. Patients had either placebo (n = 40), alive BPL1 (n = 42) or heat-killed BPL1 (n = 44). The dosage of probiotic was 1010 cfu/day (or cfu equivalent in the case of the heat-killed BPL1). No differences in baseline characteristics were observed among intervention groups.

Both BPL1 treatments (alive and heat-killed) reduced the visceral fat area (VFA), body mass index (BMI), waist circumference (WC), waist circumference to height ratio (WHtR), and conicity index (CI). Of particular interest is the reduction of visceral fat, which has been linked to a higher risk of stroke and other cardiovascular diseases.

The microbiome of subjects under BPL1 consumption also changed after treatment to a higher prevalence of Bifidobacterium and Akkermansia. These results support the effect of the strain on the modulation of the microbiome and energy metabolism.

Learn more about the research:

3-month treatment1010 cfu/day

Effects seen in both alive and heat-killed BPL1 groups

Key aspects of the trial

Main resultsSignificant reduction of waist circumference (1 – 2 cm)

Significant reduction of abdominal visceral fat (3 – 7 cm2)

Treatment/day- 300 mg of maltodextrin

- 1010 cfu BPL1 formulated in maltodextrin

- heat-killed BPL1 (equivalent 1010 cfu) formulated in maltodextrin

Placebo (n=40) BPL1 (n = 42) hk-BPL1 (n = 44)

Discovery and safety

BPL1 was isolated from the faeces of a healthy breast-fed under three months old baby. It is classified as a Bifidobacterium lactis subsp. animalis and was deposited in the Spanish cell culture collection under the code CECT 8145. Their safety has been evaluated in terms of genome sequencing – no virulent genes were found –, antibiotic resistance – MIC values under EFSA breaking points – , assays to corroborate lack of production undesired metabolites -biogenic amines-, production of D- and L- lactate and bile salt hydrolase activity. Safety was also assessed by acute ingestion assays in healthy and immunosuppressed murine models –no morbidity neither weight loss, histological issues or translocation. BPL1 is in the QPS list and has self-affirmed GRAS status in the U.S .

Our screening technology behind the identification of BPL1 was founded in the use of Caenorhabditis elegans as an in vivo model for fat reduction. Accumulated fats were quantified by fluorescence after growing the nematode in the presence of each of the 23 Lactobacillus strains and 15 Bifidobacterium. The results show the highest amount of body-fat reduction in the case of BPL1, outperforming well-established probiotic strains that were also included in the study. The effect of the strain was maintained after a heat treatment (121 °C, 30 min)

The model was also used to assess the antioxidant effect of the strain, which was remarkable when compared to control conditions. The survival assay was based on an acute oxidative stress caused by the addition of H2O2. Worms fed with BPL1 showed much more resistance towards the shock (64% survival vs 34% of control).

The effect of the strain on the nematode was further evaluated by transcriptomic and metabolic assays, which led to the conclusion that the main metabolic pathways affected were energy and lipid metabolism. Feeding behavior through tryptophan metabolism, muscle contraction and a oxidative stress and inflammation response were also identified as the main changes induced by the intake of the probiotic that are related to obesity.

BPL1 is the strain reducing fat the most. Screening for body-fat-reducing bacterial strains in C. elegans.

Protective effect of BPL1 on oxidative stress. Survival of C. elegans after oxidative shock.

Regulatory mechanisms of BPL1 assessed by transcriptomic and metabolomic approaches.

Isolated from heathy babiesFound using an in vivo model for fat reductionWorks when heat-killed

Strong anti-oxidant effect

Learn more about the research:

Key findings

POWERED BY BIOPOLIS

GRAS

QPS

Assays in other animal models

The effect of BPL1 was also tested in murine models before the human clinical trial. These assays were useful to confirm the weight reduction capabilities of the strain as well as to further evaluate the functionality of heat-killed BPL1.

Under a cafeteria diet, which reproduces a human metabolic syndrome phenotype, rats ingesting 1010 cfu equivalent/day of heat-killed BPL1 showed amelioration of mesenteric adiposity and dyslipidaemia, increase of energy expenditure and lean mass and an improved insulin sensitivity.

Under another murine model for metabolic disorders, genetically obese Zücker rats, BPL1 showed better cholesterol levels – of particular interest the total cholesterol/HDL ratio, indicative of cardiovascular risk – and a significant decrease (5 %) in body weight when compared to the obese rats not having the probiotic

The strength of BPL1 in other probiotic combinations

The strength of BPL1 has also been demonstrated when combined with other strains for a synergistic effect. Biopolis has developed specific probiotic consortia to alleviate symptoms occurring in skin disorders, such as atopic dermatitis and psoriasis. The powerful antioxidant effect of BPL1 is key to obtain a holistic bacterial product that is able to treat different aspects of the aforementioned conditions.

Atopic dermatitisIn the case of the atopic dermatitis BPL1 containing probiotic product, a drastic reduction on the consumption of corticosteroids after 6 weeks of treatment was shown in a randomized, parallel, double-blind, placebo controlled trial with 50 children aged from 4 to 17 years with moderate AD. Results of the trial, also showed a 90% clearance of the symptoms in the group taking the probiotic BPL1 containing product, compared with a 20% in the placebo group after 12-weeks. Results from this study were published in JAMA Dermatology.

PsoriasisSimilar results where obtained in the clinical trial of Biopolis probiotic product containing BPL1 specific for psoriasis. The randomized, parallel, double-blind, placebo controlled trial with 90 psoriatic patients showed a significant increase in the number of patients who have achieved a 75% or more reduction in their PASI score from baseline – the main psoriasis severity index (unpublished results).

Both cases on skin health show the potential of BPL1 as a part of a dedicated probiotic consortia, due to its great antioxidant and anti-inflammatory properties.

Reduced adiposity, body weight

Improved cardiovascular risk

Learn more about the research: Learn more about the research:

Key findings

Full scientific dossier

Pedret, A., Valls, R. M., Calderón-Pérez, L., Llauradó, E., Companys, J., Pla-Pagà, L., ... & Caimari, A. (2018). Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. International Journal of Obesity, 1.

Randomized parallel, double-blind, placebo-controlled clinical Trial on 135 abdominally obese subjects subject to BPL1 (alive or heat-killed) or placebo during a 12-week treatment. Results show a significant reduction of abdominal visceral fat, a reduction of waist circumference and a modulation of the microbiome towards an increase in Akkermansia spp. 

Carreras, N. L., Martorell, P., Chenoll, E., Genovés, S., Ramón, D., & Aleixandre, A. (2018). Anti-obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zücker fatty rats. Beneficial microbes, 1-14.

The effect of BPL1 on genetically obese (Zücker) rats was studied. Two groups of 10 rats per group were assayed - one of them serving as placebo control. BPL1 intake showed a decreased of the body weight, and ghrelin, decreased proinflammatory and oxidative stress plasma markers and decreased index for cardiovascular disease.

Caimari, A., del Bas, J. M., Boqué, N., Crescenti, A., Puiggròs, F., Chenoll, E., ... & Arola, L. (2017). Heat-killed Bifidobacterium animalis subsp. lactis CECT 8145 increases lean mass and ameliorates metabolic syndrome in cafeteria-fed obese rats. Journal of Functional Foods, 38, 251-263.

The effect of heat-killed BPL1 effect on cafeteria-fed-obese rats was studied. The trial included 4 groups (10 rats each) including placebo-controlled and standard-diet control groups. Heat-killed BPL1 ameliorated mesenteric a diposity and dyslipidaemia, as well increased energy expenditure and lean mass while also improving insulin sensitivity.

Martorell, P., Llopis, S., González, N., Chenoll, E., López-Carreras, N., Aleixandre, A., ... & Genovés, S. (2016). Probiotic strain Bifidobacterium animalis subsp. lactis CECT 8145 reduces fat content and modulates lipid metabolism and antioxidant response in Caenorhabditis elegans. Journal of agricultural and food chemistry, 64(17), 3462-3472.

Screening among >35 strains identifies BPL1 as the best performant in reducing body-fat in the model organism Caenorhabditis elegans. The efficiency of BPL1 is shown when alive and when heat-killed. Pathways modulated by the ingest of the probiotic are indentified by transcriptomics and metabolomics, being the main ones energy and fat metabolism, feed behavior and a strong antioxidant and anti-inflammatory effect.

Chenoll, E., Codoñer, F. M., Silva, A., Martinez-Blanch, J. F., Martorell, P., Ramón, D., & Genovés, S. (2014). Draft genome sequence of Bifidobacterium animalis subsp. lactis strain CECT 8145, able to improve metabolic syndrome in vivo. Genome announcements, 2(2), e00183-14.

Safety assesment by whole genomic sequencing, according to EFSA and FAO/WHO recommendations.

Navarro-López, V., Ramírez-Boscá, A., Ramón-Vidal, D., Ruzafa-Costas, B., Genovés-Martínez, S., Chenoll-Cuadros, E., ... & Codoñer-Cortés, F. M. (2018). Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA dermatology, 154(1), 37-43.

A combination of probiotic bacteria including BPL1 due to its high anti-oxidant effect, showed a significant improvement in atopic dermatitis patients, under a randomized, parallel, double-blind, placebo-controlled trial with 50 subjects.

POWERED BY BIOPOLIS

Our approach towards probiotics

A healthy microbiome supports the whole body

wellness

Constantly pushing the boundaries of technology and knowledge

ADM Biopolis at a glance

Modular, purposeful and high-performance strains

that set the new microbiome standards

ADM Biopolis was founded in 2003 as a spin-off of the National Spanish Research Council – the most important research public institution in Spain and third largest in Europe, in order to transfer the knowledge and technology of microbial research to the needs of today’s world. It is based in the Scientific Park of the University of Valencia, one of the most important biotech hubs in Europe, where knowledge and innovation are generated.

Constantly pushing the boundaries of technology and knowledge in the latest biotechnological innovations, ADM Biopolis has pioneered and led the design of new biocatalysts for a greener planet, while also discovered new bioproducts designed to improve health and wellbeing. This is possible thanks to a multidisciplinary team of scientists by training covering many different disciplines: biology, biochemistry, chemistry, biotechnology, nutrition, bioinformatics, biostatistics, food technology – but also experts on regulatory, marketing, communication and economics. Thanks to this, we explore and provide new ways of approaching people’s concerns and needs on Health & Nutrition.

ADM Biopolis has been true to its initial commitment, having worked with key partners in order to become a leading expert in biotech solutions, microbiome science, and health. Immediate world challenges require bio-based answers and ADM Biopolis is sure to be a key innovation engine behind these new solutions.

We know that we are only half human – the human body has 39 trillion bacterial cells vs. 30 trillion human cells. There is an estimated 40,000 bacterial species in the human gut, making the gastrointestinal tract the largest immune organ in our body. The majority of our bacteria reside in the colon, with the skin being the second most abundant site.

This is why at ADM Biopolis, we aim to understand the complex relationship between microbiome and health. Our sequencing technology has enabled us to identify and understand this microbial diversity. There are a different number of health indications that are completely related to our microbial behavior and to our microbiome.

We approach the development of microbiome solutions in a comprehensive way. We isolate, select, develop, and produce the right strains to initiate the specific alteration of the microbiome (dysbiosis) that is responsible for a particular health indication.

 

The microbiome helps:

· Digest food · Produce certain vitamins · Regulate our immune system · Protect against disease-causing bacteria · Maintains healthy gut lining

An imbalanced microbiome can lead to:

· Abdominal pain and bloating · Irritable Bowel Syndrome · Diarrhea · Lower Immunoregulatory · Many other specific health related issues

Immunity

DigestiveHealth

SkinHealth

MoodControl

WeightManagement

YEARS R&DEXPERIENCE

16STAFF

MEMBERS

65PhD AND

GRADUATES

85PUBLICATIONS

>100

PATENTSGROUPS

15MICROBIOMES

SEQUENCED(2ND LEADING

ORGANITZATION IN THE WORLD)

>40.000

LABS

11PRODUCTION

PLANTS

2

Our tools for success

· Specialized laboratories· Well-trained personnel· Creative ideas, rigorous approach

· A well stablished model organism for evaluation of functional ingredients· Short, reproducible lifespan – fast, robust results· Useful as a mode of action deciphering tool· Transferable to human

A great evaluation and screening tool. In order to iterate faster and with more accuracy than other companies, Biopolis uses the nematode Caenorhabditis elegans as a model to test the efficiency of probiotics and other ingredient combinations. The most important properties of this organisms are its short life-span and close molecular similarity with other animals. Experiments to identify an ingredient efficacy in C. elegans can take orders of magnitude less time than in murine models and can also be thoroughly investigated to ensure that the effect will be translated to humans. Biopolis also has robotized platforms to improve screening potency with exclusive state-of-the-art technology.

Deep know-how in microbiome science and sequencing. Biopolis is a pioneering organization in massive sequencing technologies, being the ones to have the first NGS machine entering the country. Up to today, more than 40,000 samples have been analyzed in Biopolis lab, which includes not only the sequencing but also the bioinformatic analysis of the data. This deep expertise is reflected in the more than 45 papers in peer-review journals on microbiology and microbiome. These knowledge is not only welcomed, but needed to design novel probiotic approaches and measure their efficiency on clinical trials. Of course, all of our strains are genome sequenced in-house to make sure no toxic genes are present.

· Strong in-house bioinformatics expertise· >40,000 microbiome samples analyzed· Bacterial whole-genome sequencing

· 9000 L fermentation capacity· Regular supply to clients (food+OTC)· Everything developed in-house

In-house production facilities. Many issues may appear when looking for one good probiotic strain, and not being able to grow it efficiently is possibly one of the nastiest one. That is why we are fully equipped with two production plants, DSP and QC labs to make sure our probiotics arrive to the client the way they are intended to. We meet the highest quality standards to ensure that our strains are safely used in food, pharma and baby food products.

A Strong Scientific Core. Biopolis spawns from the Spanish Research Council, the most prestigious research institution in the country, and science is in our DNA. With more than a third of PhDs in their staff, Biopolis has published over 100 scientific papers in peer-reviewed journals and 15 groups of patents. Eleven specialized laboratories are equipped with the best technology to enable putting to test the creative approaches of the team in the most rigorous way. We perform clinical trials to demonstrate that our strains work the way is intended.

Our current target health indications

InflammationCeliac disease

Boosts Immune SystemDiarrhea/rotavirus infect.

Immunity

DigestiveHealth

Bifidobacterium longum ES1Bifidobacterium infantis CECT7210

Lactobacillus paracasei CNCMI-4034Bifidobacterium breve CNCMI-4035Lactobacillus rhamnosus CNCMI-4036Bifidobacterium infantis CECT7210

Atopic DermatitisPsoriasis

Fat reductionSatiety

WeightManagement

SkinHealth

AD: Bifidobacterium lactis subsp animalis BPL1 + Bifidobacterium longum ES1 + Lactobacillus casei BPL4PS: Bifidobacterium lactis subsp animalis BPL1 + Bifidobacterium longum ES1 + Lactobacillus rhamnosus BPL15

Bifidobacterium lactis BPL1

Serotonine production and well-being

MoodControl

Bifidobacterium lactis BPL1

MaleFemale

Caries protectionOral Health

Fertility Bifidobacterium longum ES1 + Lactobacillus rhamnosus BPL15Bifidobacterium rhamnosus BPL5

Lactobacillus plantarum BPL7

With more than 16 years in probiotic product R&D, we are experts and leading providers of quality microbial technologies for the Food & Beverage, Dietary Supplement, Pharma and Infant Nutrition sectors, partnering with our clients through the whole value chain in the design and production of probiotics.

We have developed a wide range of specialty probiotic ingredients, designed to aid product developers and formulators looking to create health-targeted products. From first generation probiotic strains for immune and digestive health, to proprietary and tailored strains and blends for skin health, infant nutrition, fertility, mood control, oral health or weight management, we are able to support our partners in probiotic research, including selection and identification, through scale-up to commercial production.

ADM Biopolis represents a one-stop-shop offering integral product development, ingredient delivery technologies and suitable product matrices, constantly pushing the boundaries of technology and knowledge in the latest probiotic innovations.

Our probiotics portfolio

DISCOVER & IDENTIFICATION

FUNCTIONALITY SCREENING & VALIDATION

-Sourcing: samples from healthy humans (e.g. faeces of babies <3 months old)

-Species identification: 16S rRNA

-Whole genome sequencing

-Survival under physiological conditions: pH, bile salts

-Target functionality: in vitro models, animals, clinical trials

SCALE-UP PRODUCTION

-Optimization of production parameters: from 1L to pilot, freeze drying, specific formulations, stability testing

-Packaging-GMP, Kosher and halal-Non-GMO and Vegan-FSMA compliant

SAFETY ANALYSYS

-In vitro and in vivo studies following EFSA and WHO/FAO guidelines: antibiotic resistance, toxins & pathogenicity, animal models, additional testing upon request

We cover the whole process

Our unique methodology

Safety first

Our steps to ensure top products

When finding novel probiotic strains, safety is the first thing that we consider. We have gone the extra mile to ensure that all of our strains go through the highest quality standards, ensuring that no undesired gene or metabolic activities are present in our products. We guarantee safety by complementary approaches, using whole-genome sequencing, biochemistry experiments and animal trials.

We know that we are only half human – the human body has 39 trillion bacterial cells vs. 30 trillion human cells. There is an estimated 40,000 bacterial species in the human gut, making the gastrointestinal tract the largest immune organ in our body. The majority of our bacteria reside in the colon, with the skin being the second most abundant site.

This is why at ADM Biopolis, we aim to understand the complex relationship between microbiome and health. Our sequencing technology has enabled us to identify and understand this microbial diversity. There are a different number of health indications that are completely related to our microbial behavior and to our microbiome.

We approach the development of microbiome solutions in a comprehensive way. We isolate, select, develop, and produce the right strains to initiate the specific alteration of the microbiome (dysbiosis) that is responsible for a particular health indication. 

Our scientific approach and unique methodology has enabled us to come up with disruptive science driven results in a number of various health targets or indications.

The quality of our research thus our publications is outstanding, publishing all our work on Science Citation Index journals.

Belonging to QPS species from-Bifidobacteria-Lactobacillus

Able to survive intestinal tract-Low pH

- Bile salts

Antibiotic resistance assessed according to EFSA guidelines

Acute ingestion study in immunocompetent and

immunosuppressed mice

Whole genome sequencing and validation

No production of undesired molecules-D-lactate

-Biogenic amines-No deconjugation of bile salts

654

321

Define HealthTarget

Human ClinicalTrials

Set Probiotic Goals

Top Class Products

Library Screening

Murine ClinicalTrials

Microbiomerelation

Strain/consortiadesign

Scalability Trials5

4

3

2

1

9

8

7

6

Digestive & Gut Health, Inflammation, Celiac Disease

WeightManagement

HelicobacterPylori

10 SCI* publications 5 SCI* publications 1 SCI* publications

Immune System Atopic Dermatitis Vaginosis

9 SCI* publications 2 SCI* publications 1 SCI* publications

Rotavirus Psoriasis Male Fertility

5 SCI* publications 2 SCI* publications 1 SCI* publications

*SCI: The Science Citation Index is the citation index that describes the world’s leading journals in science, because of a rigorous selection process

Our commitment with quality

We understand society’s needs and trends

In 2014 we started our certification policy in order to ensure the highest level of quality in our probiotics. In this regard, we can proudly state that we have accomplished all the top quality certifications.

Standardization is also crucial for us. Availability and Packaging as well as documentation and logistics (transport, storage and stability) comprises one of the most important stages.

. All our probiotics are natural isolates and are not genetically modified

. We source only non-GMO ingredients for manufacturing

. We do not use any animal products in the manufacturing of our probiotics, so our products are naturally vegan

. Our products do contain no gluten, corn, soy, milk, nuts or fish ingredients

_Certificate of analysis (CoA)_Material safety data sheet (MSDS)_GMO free certificate_BSE/TSE free declarations_Stability Data_Product Data Sheet_HALAL, KOSHER certification_QPS, GMP, ISO 9001:2015, FSSC 22000, ISO 14001:2015,_Allergen-free, non-GMO, vegan

_Product supplied in vacuum-sealed bags_Bulk powder_5·1010 and 1·1011 cfu/g as standard concentrations_Refrigerated transport and storage (+2 °C to +8 °C)_24 months stored at recommended temperature range

Availabiliity and Packaging

Documentation & Certificates

Whatever the formulation in your weight management product, there is now a seal to make it even better

BPL1 is ADM's probiotic strain with significant results in visceral fat and abdominal circumference reduction. Its efficacy has been verified, both with living strains and when heat-killed, thereby providing for application in solid and in liquid formulas. This all being said, BPL1 is already a benchmark probiotic for important nutrition brands. However, if you will allow, we can also be the seal of nutritional quality that your clients are looking for.

BPL1. Let us Be Part of your products. Be Part of your brands. Be Part of your business.

www.BPL1.com

POWERED BY BIOPOLIS

POWERED BY BIOPOLIS

POWERED BY BIOPOLIS

A new generation of probiotic strains, by ADM Biopolis

BPL1 in focus